About this episode

The episode discusses the latest developments in AML therapy, focusing on the PARADIGM study and modern treatment strategies.

People in this episode

Host: Dr. Richard Schabath

Guest: Prof. Dr. Lars Bullinger

Topics covered

• AML therapy
• PARADIGM study
• chemotherapy
• triplet strategies
• clinical trials
• hematology

Keywords

• AML
• Azacitidin
• Venetoclax
• chemotherapy
• FLT3 inhibitors
• clinical trials
• hematology

Mentioned in this episode

Organizations: Charité – Universitätsmedizin Berlin

Products: Azacitidin, Venetoclax, FLT3-Inhibitoren, Gilteritinib, IDH1/2-Inhibitoren, Ivosidenib, Enasidenib, MENIN-Inhibitoren, Revumenib, Ziftomenib

More episodes of Hämatologie Shortcasts

• ASH 2025 - Aggressive B-Zell-Lymphome: Neue Optionen für ältere Patient:innen, Zelltherapien und Monitoring · February 5, 2026 · 18 min
• ASH 2025 – T-Zell-Lymphome: Neue Targets, frühe Rezidive und klinische Konsequenzen · January 19, 2026 · 29 min
• ASH 2025 – Epcoritamab & Co.: Wie sich die Therapie des follikulären Lymphoms verändert · December 19, 2025 · 20 min
• ASH 2025 - AML im Umbruch? · December 17, 2025 · 33 min
• ASH 2025 – Neuigkeiten zur CLL · December 16, 2025 · 24 min
• ASH 2025 – Latebreaker · December 4, 2025 · 34 min

Explore listener stats, chart rankings, contacts and more on the Hämatologie Shortcasts podcast page.